Table 1.
Descriptive characteristics of prostate cancer cases and controls in the PCPT
| Placebo arm | Finasteride arm | |||||
|---|---|---|---|---|---|---|
| Control (N = 848) | Case (N = 881) | P* | Control (N = 532) | Case (N = 625) | P* | |
| N (%) | ||||||
| Family history | ||||||
| No | 666 (78.5) | 700 (79.5) | 401 (75.4) | 484 (77.4) | ||
| Yes | 182 (21.5) | 181 (20.5) | 0.64 | 131 (24.6) | 141 (22.6) | 0.41 |
| Mean ± SD | ||||||
| Age at baseline, years | 63.8 ± 5.6 | 63.6 ± 5.6 | 0.58 | 64.2 ± 5.7 | 63.9 ± 5.7 | 0.29 |
| BMI, kg/m2 | 27.5 ± 3.9 | 27.1 ± 3.9 | 0.06 | 27.6 ± 3.9 | 27.5 ± 3.8 | 0.74 |
| Serum cholesterol level, mg/dl | 208.2 ± 36.7 | 211.2 ± 35.2 | 0.09 | 210.3 ± 35.4 | 208.2 ± 35.7 | 0.30 |
| Serum testosterone level, ng/dl | 374.7 ± 127.9 | 383.4 ± 130.0 | 0.16 | 380.0 ± 136.2 | 374.1 ± 132.8 | 0.46 |
| Serum estradiol level, pg/ml | 33.3 ± 10.1 | 33.7 ± 9.4 | 0.43 | 33.9 ± 10.3 | 34.1 ± 10.2 | 0.71 |
| Serum estrone level, pg/ml | 44.3 ± 14.8 | 45.3 ± 14.1 | 0.17 | 44.9 ± 14.6 | 46.7 ± 15.5 | 0.04 |
Bold values indicate significant findings.
*
P values were calculated using chi square tests for categorical variables and t-test for continuous variables.